Immunic, Inc. to Announce Financial Results for the Third Quarter …
5 days ago · Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...
Home - Immunic Therapeutics
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.
News Releases - Immunic, Inc. InvestorRoom
6 days ago · Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
Immunic, Inc. Announces Private Placement of up to $240 Million
Jan 5, 2024 · Immunic has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the securities issued in the private placement.
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 …
Feb 29, 2024 · Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today...
Immunic Highlights 2023 Accomplishments and Upcoming …
Jan 5, 2024 · Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today...
Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial …
Sep 30, 2021 · In the first quarter of 2021, Immunic announced that IMU-838 showed evidence of clinical activity in its phase 2 CALVID-1 trial in hospitalized patients with moderate COVID-19.
Immunic Announces Positive Results from Single and Multiple …
NEW YORK, Sept. 20, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced positive unblinded safety, tolerability and pharmacokinetic (PK) results from Part A ...
Immunic to Participate in Industry, Scientific and Investor …
Oct 29, 2024 · November 19-21: Immunic's management, business development and investor relations teams will be hosting one-on-one meetings in London in connection with the Jefferies London Healthcare Conference ...
Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical ...
May 5, 2022 · a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the...
- Some results have been removed